Precautions and potential risk warnings when taking rasagiline (Azilai)

Rasagiline (Rasagiline) is a selective monoamine oxidaseB inhibitor (MAO-B inhibitor), mainly used for Parkinson’s disease (Parkinson’s Disease, Treatment of PD) can delay the degradation of dopamine and increase dopamine levels in the central nervous system, thereby improving the motor symptoms of Parkinson's disease, such as tremor, stiffness and bradykinesia. Since its mechanism of action involves the regulation of neurotransmitter metabolism, patients need to pay attention to multiple medication precautions and potential risks during medication to ensure treatment safety and maximize efficacy.

First of all, rasagiline should be taken strictly in accordance with medical advice, usually once a day, orally and swallow the whole tablet. It can be taken with food, but it should not be used at the same time with high tyrosine-containing foods or other MAO inhibitors to prevent blood pressure from rising or hypertensive crisis. Patients should truthfully inform their doctors of their past medication history and comorbid conditions before starting medication, especially patients with hypertension, cardiovascular disease, abnormal liver and kidney function, or mental illness. They need to assess risks and adjust dosages under the guidance of a doctor.

Secondly, potential adverse reactions include dizziness, insomnia, nausea, hypotension, mild hallucinations and occasional symptoms of anxiety or depression. Most patients tolerate these reactions, but some may develop severe blood pressure fluctuations, cardiac arrhythmias, or behavioral abnormalities. While taking the medicine, blood pressure, heart rate and mental state should be monitored regularly, especially for elderly patients or those with underlying cardiovascular diseases. If serious adverse reactions occur, you should contact your doctor promptly and adjust the dose or discontinue the drug if necessary.

Drug interactions are another important point in the use of rasagiline. Concomitant use of rasagiline with other MAO inhibitors, tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), dextroamphetamine-containing drugs, and certain cough or cold medications may cause serotonin syndrome or severe blood pressure reactions. Therefore, during treatment, patients should list all the drugs they are taking in detail to their doctor, and adjust or replace them under the guidance of the doctor. At the same time, patients need to avoid abusing dietary supplements or high-protein foods containing tyrosine to reduce the risk.

In long-term treatment management, rasagiline can be used alone or in combination with levodopa to extend treatment"On time" and mitigating motion fluctuations. The effects usually begin to show after several weeks of continuous use, but the best results need to be maintained on the basis of stable dosage and regular medication. Patients should undergo regular follow-up during treatment to evaluate motor symptoms, quality of life and adverse reactions. Doctors will adjust the dose or combine it with other drugs in a timely manner based on the patient's tolerance, disease progression and side effects to achieve individualized treatment goals.

In summary, rasagiline, as a commonly used targeted drug for Parkinson's disease, has significant advantages in improving motor symptoms and delaying the course of the disease. However, safe medication must be based on strict compliance with dosage, attention to drug interactions, and regular monitoring of blood pressure and psychological status. Through scientific management of the medication process, timely handling of adverse reactions and individualized adjustment of treatment plans, patients can benefit from the clinical efficacy of rasagiline to the greatest extent while ensuring safety.

Reference link:https://www.drugs.com